Prognostic Value and Clinicopathological Roles of Phenotypes of Tumour-associated Macrophages in Colorectal Cancer

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2019 Oct 26

PMID 31650222

Citations 22

Authors

Yamei Zhao

Xiaoxu Ge

Xiaoming Xu

Shaojun Yu

Jian Wang

Lifeng Sun

Affiliations

Soon will be listed here.

Abstract

Background: The role of tumour-associated macrophages (TAMs) in predicting the prognosis of colorectal cancer (CRC) remains controversial. This is especially so because the prognostic significance and clinicopathological relevance of different subtypes of TAMs in the immune microenvironment of CRC have not yet been established.

Objective: To assess the clinicopathological and prognostic value of pan-macrophages, M1-macrophages or M2-macrophages in patients with CRC.

Methods: Comprehensive searched on the Medline/PubMed, Web of Science (WoS) and Google Scholar databases was conducted to identify relevant studies published up to April 2019. The association between overall survival (OS), cancer-specific survival (CSS) or disease-free survival (DFS) and TAMs was analysed by meta-analysis.

Results: A total of 3749 patients from 17 studies were included. The pooled hazard ratios (HRs) indicated that high-density pan-macrophages improved OS (HR 0.67, P = 0.02). The pooled HR for M2-macrophages showed that high M2-macrophages infiltration was significantly associated with shorter OS (HR 2.93, P < 0.0001) and DFS (HR 2.04, P = 0.02). The pooled odds ratios (ORs) revealed that high-density TAMs was associated with high CD8+ T cell infiltration (OR 2.04, P = 0.007), no distant metastasis (NDM) (OR 0.38, P < 0.0001), microsatellite instability-high (MSI-H) (OR 0.38, P = 0.001), no lymph node metastasis (NLNM) (OR 0.54, P = 0.0002) and non-mucinous cancer (OR 0.39, P < 0.00001).

Conclusions: Unlike other solid tumours, high-density CD68+ macrophage infiltration can be a good prognostic marker for CRC. However, when macrophages act as targets of combination therapy in CRC treatment, this might be more effective for CRC patients with high CD8+ T cell infiltrate, NDM, MSI-H, NLNM and non-mucinous cancer.

Citing Articles

Computational pathology applied to clinical colorectal cancer cohorts identifies immune and endothelial cell spatial patterns predictive of outcome.

Trahearn N, Sakr C, Banerjee A, Lee S, Baker A, Kocher H J Pathol. 2025; 265(2):198-210.

PMID: 39788558 PMC: 11717494. DOI: 10.1002/path.6378.

Spatial transcriptomic analysis reveals local effects of intratumoral fusobacterial infection on DNA damage and immune signaling in rectal cancer.

Duggan W, Kisakol B, Woods I, Azimi M, Dussmann H, Fay J Gut Microbes. 2024; 16(1):2350149.

PMID: 38709233 PMC: 11086019. DOI: 10.1080/19490976.2024.2350149.

Gut microbiota and their derivatives in the progression of colorectal cancer: Mechanisms of action, genome and epigenome contributions.

Ahmad A, Mahmood N, Raza M, Mushtaq Z, Saeed F, Afzaal M Heliyon. 2024; 10(8):e29495.

PMID: 38655310 PMC: 11035079. DOI: 10.1016/j.heliyon.2024.e29495.

Macrophage's role in solid tumors: two edges of a sword.

Jahandideh A, Yarizadeh M, Masjedi M, Fatehnejad M, Jahandideh R, Soheili R Cancer Cell Int. 2023; 23(1):150.

PMID: 37525217 PMC: 10391843. DOI: 10.1186/s12935-023-02999-3.

Increased Fusobacterium tumoural abundance affects immunogenicity in mucinous colorectal cancer and may be associated with improved clinical outcome.

Duggan W, Salvucci M, Kisakol B, Lindner A, Reynolds I, Dussmann H J Mol Med (Berl). 2023; 101(7):829-841.

PMID: 37171483 PMC: 10300184. DOI: 10.1007/s00109-023-02324-5.

References

Teng F, Tian W, Wang Y, Zhang Y, Guo F, Zhao J . Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis. J Hematol Oncol. 2016; 9:8. PMC: 4744391. DOI: 10.1186/s13045-015-0231-4. View

Franklin R, Liao W, Sarkar A, Kim M, Bivona M, Liu K . The cellular and molecular origin of tumor-associated macrophages. Science. 2014; 344(6186):921-5. PMC: 4204732. DOI: 10.1126/science.1252510. View

de Ruiter E, Ooft M, Devriese L, Willems S . The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis. Oncoimmunology. 2017; 6(11):e1356148. PMC: 5674970. DOI: 10.1080/2162402X.2017.1356148. View

Yuan X, Zhang J, Li D, Mao Y, Mo F, Du W . Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis. Gynecol Oncol. 2017; 147(1):181-187. DOI: 10.1016/j.ygyno.2017.07.007. View

Fu Q, Chen N, Ge C, Li R, Li Z, Zeng B . Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis. Oncoimmunology. 2019; 8(7):1593806. PMC: 6527267. DOI: 10.1080/2162402X.2019.1593806. View

Bailey C, Negus R, Morris A, Ziprin P, Goldin R, Allavena P . Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clin Exp Metastasis. 2007; 24(2):121-30. DOI: 10.1007/s10585-007-9060-3. View

Tan S, Fan Y, Luo H, Shen Z, Guo Y, Zhao L . Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer. World J Gastroenterol. 2005; 11(8):1210-4. PMC: 4250716. DOI: 10.3748/wjg.v11.i8.1210. View

Khorana A, Ryan C, Cox C, Eberly S, Sahasrabudhe D . Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. Cancer. 2003; 97(4):960-8. DOI: 10.1002/cncr.11152. View

Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D . Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2008; 27(2):186-92. DOI: 10.1200/JCO.2008.18.7229. View

10.

Banerjee A, Chabria Y, Kanna N R R, Gopi J, Rowlo P, Sun X . Role of Tumor Specific niche in Colon Cancer Progression and Emerging Therapies by Targeting Tumor Microenvironment. Adv Exp Med Biol. 2019; 1341:177-192. DOI: 10.1007/5584_2019_355. View

11.

Qian B, Pollard J . Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141(1):39-51. PMC: 4994190. DOI: 10.1016/j.cell.2010.03.014. View

12.

Kawachi A, Yoshida H, Kitano S, Ino Y, Kato T, Hiraoka N . Tumor-associated CD204 M2 macrophages are unfavorable prognostic indicators in uterine cervical adenocarcinoma. Cancer Sci. 2017; 109(3):863-870. PMC: 5834786. DOI: 10.1111/cas.13476. View

13.

Pages F, Mlecnik B, Marliot F, Bindea G, Ou F, Bifulco C . International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018; 391(10135):2128-2139. DOI: 10.1016/S0140-6736(18)30789-X. View

14.

Srivastava K, Hu J, Korn C, Savant S, Teichert M, Kapel S . Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth. Cancer Cell. 2014; 26(6):880-895. DOI: 10.1016/j.ccell.2014.11.005. View

15.

Alves A, Diel L, Lamers M . Macrophages and prognosis of oral squamous cell carcinoma: A systematic review. J Oral Pathol Med. 2017; 47(5):460-467. DOI: 10.1111/jop.12643. View

16.

Gonzalez H, Hagerling C, Werb Z . Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018; 32(19-20):1267-1284. PMC: 6169832. DOI: 10.1101/gad.314617.118. View

17.

Mei Z, Liu Y, Liu C, Cui A, Liang Z, Wang G . Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer. 2014; 110(6):1595-605. PMC: 3960618. DOI: 10.1038/bjc.2014.46. View

18.

Xiong Y, Wang K, Zhou H, Peng L, You W, Fu Z . Profiles of immune infiltration in colorectal cancer and their clinical significant: A gene expression-based study. Cancer Med. 2018; 7(9):4496-4508. PMC: 6144159. DOI: 10.1002/cam4.1745. View

19.

Li S, Xu F, Zhang J, Wang L, Zheng Y, Wu X . Tumor-associated macrophages remodeling EMT and predicting survival in colorectal carcinoma. Oncoimmunology. 2018; 7(2):e1380765. PMC: 5798198. DOI: 10.1080/2162402X.2017.1380765. View

20.

Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A . PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509-20. PMC: 4481136. DOI: 10.1056/NEJMoa1500596. View